TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06644300: A Phase I, Multicenter, Non-randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BM230 in Patients With Advanced Solid Tumors

Sponsor: Suzhou Biomissile Pharmaceuticals Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 123 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06644300 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06644300 Rescue Dossier →